STOCK TITAN

NASDAQ: FATE Lawsuit Alert: Long Term Investors who hold shares of Fate Therapeutics, Inc. should contact the Shareholders Foundation

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

SAN DIEGO, CA / ACCESSWIRE / February 28, 2023 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in NASDAQ:FATE shares.

However, investors who purchased Fate Therapeutics, Inc. (NASDAQ:FATE) shares prior to April 2, 2020, and continue to hold any of those NASDAQ:FATE shares, have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On January 21, 2023, a lawsuit was filed on behalf of certain investors in NASDAQ:FATE shares over alleged Securities Laws Violations by Fate Therapeutics, Inc. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose that the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors, that accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources, that as a result, Fate had overstated the impact of the Janssen Collaboration Agreement's on Fate's long-term clinical and commercial profitability, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased Fate Therapeutics, Inc. (NASDAQ:FATE) shares should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

SOURCE: Shareholders Foundation, Inc.



View source version on accesswire.com:
https://www.accesswire.com/741119/NASDAQ-FATE-Lawsuit-Alert-Long-Term-Investors-who-hold-shares-of-Fate-Therapeutics-Inc-should-contact-the-Shareholders-Foundation

Fate Therapeutics, Inc.

NASDAQ:FATE

FATE Rankings

FATE Latest News

FATE Stock Data

461.96M
80.71M
1.47%
91.78%
14.49%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About FATE

fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.